Conceptualizing Guidelines to Manage Patients with HR–Positive, HER2-Negative Early Breast Cancer

Management of HR-Positive/HER2-Negative Early Breast Cancer: Taking Direction From the Updated Gu...Подробнее

Important considerations in the management of HR+, HER2-negative early breast cancerПодробнее

Assessing Risk in Hormone Receptor-Positive/HER2-Negative Early Breast Cancer: How to Approach Ch...Подробнее

Recent Updates in HR-Positive/HER2-Negative Early Breast Cancer: A Deep Dive Into Understanding t...Подробнее

Optimizing treatment in patients with early-stage HER2-positive breast cancerПодробнее

Managing the Borderline-Risk Patient With Hormone Receptor-Positive/HER2-Negative Early Breast Ca...Подробнее

ASCO 2023 Expert Report in HR positive, HER2 negative breast cancer by Catherine Harper-WynneПодробнее

OlympiA Study Demonstrates the Efficacy of Olaparib in the Treatment of Early Breast CancerПодробнее

Understanding the Concerns and Challenges of Patients With HR-Positive/HER2-Negative EBC: Expert ...Подробнее

Management of premenopausal HR+/HER2- breast cancer with micro-metastasisПодробнее

Optimizing adjuvant treatment in HR+/HER2- early breast cancerПодробнее

ELEANOR: real-world study of extended adjuvant neratinib in HER2+/HR+ early breast cancerПодробнее

The Role of Biomarkers in HR-Positive/HER2-Negative Early Breast Cancer: From Clinical Analysis t...Подробнее

Key challenge associated with the management of HR+/HER2- breast cancerПодробнее

Guideline Updates for Extended Endocrine Therapy Decision-Making in HR+, Early-Stage Breast CancerПодробнее

Advances and considerations in the treatment and management of HR+, HER2-, advanced breast cancerПодробнее

What Are the Treatment Options for Early Stage Breast Cancer?Подробнее

What's new for hereditary breast cancer treatment?Подробнее

Multidisciplinary Team Best Practices to Improve Adherence for High-Risk, HR-Positive/HER2-Negati...Подробнее